Brilinta
News/ News/ Sales and Marketing
FDA grants fast review of AZ’s Brilinta to prevent recurring strokes
Richard Staines
AstraZeneca, Brilinta, cardiovascular, Eli Lilly, fda, stroke
0 Comment
AZ claims FDA okay for Brilinta in coronary artery disease patients
Phil Taylor
AstraZeneca, Brilinta, cardiovascular, FDA approval
0 Comment
New heart attack data boost AZ’s Brilinta
Andrew McConaghie
AstraZeneca, Brilinta, cardiology, ESC2017, European Society of Cardiology
0 Comment
A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
AstraZeneca/ News/ Sales and Marketing
AZ feels pain after heart drug fails again
Richard Staines
Brilinta, cardiovascular
0 Comment
Brilinta will not hit $3.5bn sales target, company admits.
Brilique boosted by NICE’s long-term prevention recommendation
Andrew McConaghie
AstraZeneca, Brilinta, Brilique
0 Comment
Recommendation will add to growth trajectory